TAK 632 98%

TAK 632

MedMol
S81252
1228591-30-7
C27H18F4N4O3S
554.52
1SU; TAK-632; N-(7-cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide; S7291; N-{7-cyano-6-[4-fluoro-3-({[3-(trifluoromethyl)phenyl]acetyl
品牌 货号 产品规格 价格(RMB) 库存(上海) 北京 武汉 南京 购买数量
MedMol S81252-2mg 98% ¥200.00元 10 - - -
MedMol S81252-5mg 98% ¥300.00元 9 - - -
MedMol S81252-10mg 98% ¥400.00元 8 - - -
MedMol S81252-25mg 98% ¥890.00元 10 - - -
MedMol S81252-50mg 98% ¥1720.00元 >10 - - -
源叶(MedMol) S81252-100mg 98% ¥2600.00元 预计交期:2-3天 - - -
产品介绍 参考文献 质检证书(COA) 摩尔浓度计算器 相关产品

产品介绍

TAK-632 is a potent pan-RAF inhibitor with IC50 of 1.4, 2.4 and 8.3 nM for CRAF, BRAFV600E, BRAFWT, respectively.
产品描述: TAK-632 is a potent pan-RAF inhibitor with IC50 of 1.4, 2.4 and 8.3 nM for CRAF, BRAFV600E, BRAFWT, respectively.
靶点: c-Raf:1.4 nM (IC50);Braf:8.3 nM (IC50);Aurora B:66 nM (IC50);PDGFRβ:120 nM (IC50);PDGFRα:610 nM (IC50);FGFR3:280 nM (IC50);TIE2:740 nM (IC50);IKKβ:3700 nM (IC50);CDK1:790 nM (IC50);CDK2:580 nM (IC50);p38α:600 nM (IC50);GSK3β:500 nM (IC50);MEK1:3700 nM (IC50);Raf; FGFR; PDGFR; AuroraKinase
体内研究: TAK-632 demonstrates dramatically improved solubility (740 μg/mL) in pH 6.8 phosphate buffer and exhibits significant oral absorption (at a dose of 25 mg/kg, AUC, 32.47 μg h/mL; F, 51.7%) in rats. In a dog PK study, 10 mg/kg administration of TAK-632 also shows superior oral bioavailability (F: 108%).Oral single administration of TAK-632 inhibits pERK in tumors at 8 h after its administration over a dose range of 1.9-24.1 mg/kg. In particular, 9.7-24.1 mg/kg dosing with TAK-632 strongly inhibits pERK levels to 11% of the control. TAK-632 exhibits dose-dependent antitumor efficacy without severe body weight reduction over a dose range of 3.9-24.1 mg/kg. Significant tumor regression is observed at 9.7 mg/kg and 24.1 mg/kg (T/C=−2.1% and −12.1%, respectively). TAK-632 exhibits potent antitumor efficacy when orally administered at 60 mg/kg once daily (T/C=37%, P<0.001) or at 120 mg/kg once daily (T/C=29%, P<0.001) for 21 days without severe toxicity in NRAS-mutant melanoma using a SK-MEL-2 xenograft model
参考文献: 1. Okaniwa M, et al. Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives. J Med Chem. 2013 Aug 22;56(16):6478-94. 2. Nakamura A, et al. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Cancer Res. 2013 Oct 11.
溶解性: DMSO  :  100  mg/mL  (180.34  mM;  Need  ultrasonic)
保存条件: 2-8℃
配置溶液浓度参考:
1mg 5mg 10mg
1 mM 1.803 ml 9.017 ml 18.034 ml
5 mM 0.361 ml 1.803 ml 3.607 ml
10 mM 0.18 ml 0.902 ml 1.803 ml
50 mM 0.036 ml 0.18 ml 0.361 ml
注意: 部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。

参考文献

质检证书(COA)

如何获取质检证书(COA)?
请输入货号和一个与之匹配的批号。
例如:
批号:JS298415 货号:S20001-25g
在货品标签上如何找到货号和批号?

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)

=
×
×

相关产品